PDCD1 and melanoma: The same anti-PD-1 agents are also prescribed in an adjuvant setting for completely resected melanoma with lymph node involvement or metastatic disease [81] and are currently under investigation as neoadjuvant treatment [82,83,84] for resectable stage III melanoma.